LAUSR

Alzheimer disease (AD) is an age-associated clinical condition marked by neuropathologic β-amyloid plaque and tau accumulation, deterioration in episodic memory and other cognitive abilities, and decline in functional living abilities. According to the newly released 2019 Alzheimer's Association Facts and Figures,1 AD now affects 5.8 million people in the United States, a new case of AD occurs every 65 seconds, and 1 in 3 older adults will die of AD or another form of dementia. Blacks and Hispanics are at a disproportionately higher risk for AD, and the cost due to this disease in the United States alone is estimated to be over $290 billion dollars. The profound individual and social burden of AD points decidedly to the need for better characterization of the preclinical phase to develop, monitor, and test the efficacy of clinical interventions designed to ameliorate this growing public health crisis.